Lymphocytic enzymes and lipid peroxidation in patients with metabolic syndrome

Clinical Biochemistry

Volumn 45, Issue 13-14, 2012, Pages 1081-1085

  De Bona, Karine S ^a   Bonfanti, Gabriela ^a   Cargnelutti, Lariane O ^a   Bitencourt, Paula E R ^a   da Silva, Priscila S ^a   Ceolin, Ronise ^a   Pimentel, Victor C ^a   Moretto, Maria Beatriz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Acetylcholinesterase; Adenosine deaminase; Dipeptidyl peptidase IV; Lipid peroxidation; Lymphocytes; Metabolic syndrome

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE DEAMINASE; DIPEPTIDYL PEPTIDASE IV; GAMMA GLUTAMYLTRANSFERASE; INSULIN; N ACETYL BETA GLUCOSAMINIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CELL ISOLATION; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; LYMPHOCYTE; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; BETA-N-ACETYL-GALACTOSAMINIDASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIPEPTIDYL PEPTIDASE 4; ENZYME ACTIVATION; ENZYME ASSAYS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFLAMMATION; INSULIN; LIPID PEROXIDATION; LYMPHOCYTES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84866042386     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.06.010     Document Type: Article

References (40)

1. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
2. Knuiman M.W., Hung J., Divitini M.L., Davis T.M., Beilby J.P. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prev Rehabil 2009, 16:235-241.
3. Alba A.C., Delgado D.H. Optimal medical treatment of cardiovascular risk factors: can we prevent the development of heart failure?. Expert Rev Cardiovasc Ther 2009, 7:147-157.
4. Hansel B., Giral P., Nobecourt E., Chantepie S., Bruckert E., Chapman M.J., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004, 89:4963-4971.
5. Jacobs M., Van Greevenbroek M.M.J., Van Der Kallen C.J.H., Ferreira I., Blaak E.E., Feskens E.J., et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009, 39:437-444.
6. Kuno M., Seki N., Tsujimoto S., Nakanishi I., Kinoshita T., Nakamura K., et al. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. Eur J Pharmacol 2006, 534:241-249.
7. Haskó G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004, 25:33-39.
8. Duncker D.J., Bache R.J. Regulation of coronary blood flow during exercise. Physiol Rev 2008, 88:1009-1086.
9. Pacheco R., Martinez-Navio J.M., Lejeune M., Climent N., Oliva H., Gatell J.M., et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci 2005, 102:9583-9588.
10. Sullivan J.L., Osborne W.R., Wedgwood R.J. Adenosine deaminase activity in lymphocytes. Br J Haematol 1977, 122:216-220.
11. Franco R., Casado V., Ciruela F., Saura C., Mallol J., Canela E.I., et al. Cell surface adenosine deaminase much more than an ectoenzyme. Prog Neurobiol 1997, 52:283-294.
12. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
13. Kameoka J., Tanaka T., Nojima Y., Schlossman S.F., Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993, 261:466-469.
14. Tayebati S.K., El-Assouad D., Ricci A., Amenta F. Immunological and immunocytochemical characterization of cholinergic markers in human peripheral blood lymphocytes. J Neuroimmunol 2002, 132:147-155.
15. Santos S.C.R., Vala I., Miguel C., Barata J.T., Garção P., Agostinho P., et al. Expression and subcellular localization of a novel nuclear acetylcholinesterase protein. J Biol Chem 2007, 282:597-603.
16. Paleari L., Grozio A., Cesario A., Russo P. The cholinergic system and cancer. Semin Cancer Biol 2008, 18:211-217.
17. Lee D.S., Evans J.C., Robins S.J., Wilson P.W., Albano I., Fox C.S., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133.
18. Reiner R.G., Tanner A.R., Keyhani A.H., Wright R. A comparative study of lysosomal enzyme activity in monocytes and Kupffer cells isolated simultaneously in a rat model of liver injury. Clin Exp Immunol 1981, 43:376-380.
19. Hirokawa K. Age-related changes of signal transduction in T cells. Exp Gerontol 1999, 34:7-18.
20. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of concentration of low-density lipoprotein in plasma, without use of preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
23. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968, 97:77-89.
24. Giusti G., Gakis C. Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme 1971, 12:417-425.
25. Schön E., Demuth H.U., Barth A., Ansorge S. Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycylproline p-nitroanilide in T-lymphocytes. Biochem J 1984, 223:255-258.
26. Ellman G.L., Courtney D.K., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
27. Fritzgerald B.B., Costa L.G. Modulation of muscarinic receptors an acetylcholinesterase activity in lymphocytes and brain areas following repeated organophosphate exposure in rats. Fundam Appl Toxicol 1993, 20:210-216.
28. Xavier D.O., Amaral L.S., Gomes M.A., Rocha M.A., Campos P.R., Cota B.D., et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 2010, 64:220-225.
29. Lapenna G.D., Ciofani S.D., Pierdomenico M.A., Giamberardino M.A., Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 2001, 31:331-335.
30. Bodin P., Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 1998, 47:351-354.
31. Schwabe U., Schonhofer P.S., Ebert R. Facilatation by adenosine of the action of insulin on the accumulation of adenosine 3',5'-monophosphate lipolysis and glucose oxidation in isolated fat cells. Eur J Biochem 1974, 46:537.
32. Fredholm B.B. Effect of adenosine, adenosine analogues and drugs inhibiting adenosine inactivation on lipolysis in rat fat cells. Acta Physiol Scand 1978, 102:191-198.
33. Elgün S., Keskinege A., Yilmaz E. Tissue dipeptidyl peptidase IV and adenosine deaminase activities in benign prostatic hypertrophyand prostate cancer. Cancer Res Ther Control 2001, 11:107-111.
34. De Meester I., Vanham G., Kestens L., Vanhoof G., Bosmans E., Gigase P., et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994, 24:566-570.
35. Bellé L.P., Bitencourt P.E.R., De Bona K.S., Zanette R.A., Moresco R.N., Moretto M.B. Expression of CD26 and its association with dipeptidyl peptidase IV activity in lymphocytes of type 2 diabetes patients. Cell Biochem Biophys 2011, 61:297-302.
36. Kirino Y., Sato Y., Kamimoto T., Kawazoe K., Minakuchi K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab 2011, 300:372-379.
37. Satapathy S.K., Ochani M., Dancho M., Hudson L.K., Rosas-Ballina M., Valdes-Ferrer S.I., et al. Galantamine alleviates inflammation and other obesity- associated complications in high-fat diet-fed mice. Mol Med 2011, 17:599-606.
38. Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I., et al. Hyperglycaemia increases dipeptidy peptidase IV activity in diabetes mellitus. Diabetologia 2005, 48:1168-1172.
39. Pérez-Matute P., Zulet M.A., Martínez J.A. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol 2009, 9:771-779.
40. Jover A., Corbella E., Munõz A., Millán J., Pintó X., Mangas A., et al. Prevalence of metabolic syndrome and its components in patients with acute coronary syndrome. Rev Esp Cardiol 2011, 64:579-586.